Hemodynamics and Extravascular Lung Water in Acute Lung Injury (HEAL)
Acute Lung Injury
About this trial
This is an interventional treatment trial for Acute Lung Injury focused on measuring Acute Lung Injury, Extravascular Lung Water, Acute Respiratory Distress Syndrome
Eligibility Criteria
Inclusion Criteria:
Acute onset of:
- PaO2/FiO2 less than or equal to 300.
- Bilateral infiltrates consistent with pulmonary edema on the frontal chest radiograph.
- Requirement for positive pressure ventilation through an endotracheal tube or tracheostomy.
- No clinical evidence of left atrial hypertension that would explain the pulmonary infiltrates. If measured, pulmonary arterial wedge pressure less than or equal to 18 mmHg.
Exclusion Criteria:
- Age younger than 18 years old.
- Greater than 24 hours since all inclusion criteria first met.
- Neuromuscular disease that impairs ability to ventilate without assistance, such as C5 or higher spinal cord injury, amyotrophic lateral sclerosis, Guillain-Barré syndrome, myasthenia gravis, or kyphoscoliosis (see Appendix I.A).
- Pregnancy (negative pregnancy test required for women of child-bearing potential).
- Severe chronic respiratory disease (see Appendix I.C).
- Severe Chronic Liver Disease (Child-Pugh 11 - 15, see Appendix I.E)
- Weight > 160 kg.
- Burns greater than 70% total body surface area.
- Malignancy or other irreversible disease or conditions for which 6-month mortality is estimated to be greater than 50 % (see Appendix I.A).
- Known cardiac or vascular aneurysm.
- Contraindications to femoral arterial puncture - platelets < 30, bilateral femoral arterial grafts, INR > 3.0.
- Not committed to full support.
- Participation in other experimental medication trial within 30 days.
- Allergy to intravenous lasix or any components of its carrier.
- History of severe CHF - NYHA class ≥ III, previously documented EF < 30%.
- Diffuse alveolar hemorrhage.
- Presence of reactive airway disease (active will be defined based on recent frequency and amounts of MDI's use and steroids to control the disease).
Sites / Locations
- Kaiser Permanente Sunnyside
- Legacy Good Samaritan
- Oregon Health and Science University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Modified FACTT (control)
EVLW
The investigators control arm consists of a simplified algorithm for conservative management of fluids in patients with ALI, as to be published by the ARDSnet group, based on the protocol used in the FACTT trial. The protocol calls for strict adherence to ARDSnet ventilation, our weaning protocol and use of only select vasoactive, beta-adrenergic drugs as it is felt that variation in these treatments could seriously confound our results. Albuterol administration will not be permitted in the either arm except for life threatening bronchospasm not responsive to ipratropium. Ipratropium may be administered at the treating physician's discretion for bronchospasm. PiCCO's will be placed in each control patient and data recorded twice daily. The treating physician's will be blinded to this data.
When EVLW exceeds 9 ml/kg PBW the algorithmic treatment is begun and continued until EVLW ≤9 ml/kg PBW or extubation whichever comes first as tolerated (see figure 6). Furosemide and volume contraction are initiated when sufficient volumetric preload (GEDI) is available to enact volume contraction as a means to decrease measured EVLW without causing concomitant hypoperfusion. Fluid administration is also guided by changes in EVLW. An increase in EVLW > 2ml/kg PBW as a result of fluid administration curtails any further fluid administration until the next scheduled measurement. Our ultimate treatment goal is to maximally lower EVLW towards the normal range - thus improving lung mechanics and gas exchange - without causing concomitant hemodynamic compromise and end-organ injury. By doing so we feel this algorithmic, goal directed, therapeutic approach should improve outcome.